According to the invention, there is provided a pharmaceutically-acceptable composition which is preferably in the form of a spray-dried powder comprising a mixture of:
(fffffffffffff) a pharmacologically-effective dosage amount of at least one pharmaceutically-active compound; and
(ggggggggggggg) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material.
According to the invention, there is provided a pharmaceutically-acceptable composition which is preferably in the form of a spray-dried powder comprising a mixture of:
(fffffffffffff) a pharmacologically-effective dosage amount of at least one pharmaceutically-active compound; and
(ggggggggggggg) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material.
Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Pharmaceutical preparations. Development of pharmaceutical preparations; research and
development in the pharmaceutical fields; research and
development of drug delivery platforms. Licensing of intellectual property.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Pharmaceutical preparations. Development of pharmaceutical preparations; research and development in the pharmaceutical fields; research and development of drug delivery platforms. Licensing of intellectual property.
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
Disclosed is a needle-free applicator that is suitable for administering a solid, amorphous, mono-particulate powder composition into a body cavity of a human patient, which cavity includes a mucosal surface, wherein the applicator comprises:
(i) an opaque reservoir comprising said powder composition;
(ii) an optional actuating means for generating a force upon actuation of the device by a user; and
(iii) a dispensing means through which, following said actuation, said powder composition may be dispensed,
wherein said powder composition comprises a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material; and
which powder composition is less than about 4% chemically degraded after storage for:
(a) at least about 3 months at 40° C. and 75% relative humidity; and/or
(b) at least about 18 months at below about 30° C.; and/or
(c) at least about 18 hours at above about 1 million lux of UV light.
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15.
Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medical preparation for use as a narcotic antagonist in the treatment of narcotic overdose; Drug delivery devices, namely, nasal delivery devices sold filled with pharmaceutical preparations for use in the treatment of narcotic overdose; Pharmaceutical preparations in the form of powders for treatment of opioid addiction and overdose.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medical preparation for use as a narcotic antagonist in the treatment of narcotic overdose; Drug delivery devices, namely, nasal delivery devices sold filled with pharmaceutical preparations for use in the treatment of narcotic overdose; Pharmaceutical preparations in the form of powders for treatment of opioid addiction and overdose.
According to the invention, there is provided a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of a small molecule CGRP receptor antagonist, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for, for example, transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred CGRP receptor antagonists include the gepants, such as ubrogepant, atogepant, rimegepant and zavegepant. The compositions are thus particularly useful in the treatment of migraine related conditions.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
According to the invention, there is provided a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin, which solid compositions, when dissolved in aqueous media, exhibit a pH of between about 4.5 and about 8.0. Said compositions are suitable for, for example, transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and the maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode. The method comprises treating the subject with an opioid agonist whilst managing their depression or depressive disorder using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
The present disclosure is directed to a method of combatting opioid dependence in a subject who is misusing alcohol or susceptible to alcohol misuse. The method comprises treating the subject with an opioid agonist whilst managing their alcohol consumption using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 9/00 - Medicinal preparations characterised by special physical form
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
(b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material.
Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.
Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
According to the invention, there is provided a needle-free applicator that is suitable for administering a solid, amorphous, mono-particulate powder composition into a body cavity of a human patient, which cavity includes a mucosal surface, wherein the applicator comprises: (I) an opaque reservoir comprising said powder composition; (ii) an optional actuating means for generating a force upon actuation of the device by a user; and (iii)a dispensing means through which, following said actuation, said powder composition may be dispensed, wherein said powder composition comprises a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material; and which powder composition is less than about 4% chemically degraded after storage for: (a) at least about 3 months at 40°C and 75% relative humidity; (b) at least about 18 months at below about 30°C; and/or (c) at least about 18 hours at above about 1 million lux of UV light. Compositions for use in the applicator are preferably made by way of spray drying and the carrier material may include a disaccharide, such as lactose or trehalose, and a maltodextrin, which may be spray-dried together in combination with the active ingredient. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
According to the invention, there is provided a needle-free applicator that is suitable for administering a solid, amorphous, mono-particulate powder composition into a body cavity of a human patient, which cavity includes a mucosal surface, wherein the applicator comprises: (I) an opaque reservoir comprising said powder composition; (ii) an optional actuating means for generating a force upon actuation of the device by a user; and (iii)a dispensing means through which, following said actuation, said powder composition may be dispensed, wherein said powder composition comprises a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material; and which powder composition is less than about 4% chemically degraded after storage for: (a) at least about 3 months at 40°C and 75% relative humidity; (b) at least about 18 months at below about 30°C; and/or (c) at least about 18 hours at above about 1 million lux of UV light. Compositions for use in the applicator are preferably made by way of spray drying and the carrier material may include a disaccharide, such as lactose or trehalose, and a maltodextrin, which may be spray-dried together in combination with the active ingredient. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
According to the invention, there is provided a solid, amorphous mono-particulate powder composition comprising a pharmacologically-effective dosage amount of atropine, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material. The compositions are preferably made by way of spray drying and the carrier material may include a disaccharide, such as lactose or trehalose, and a maltodextrin, which may be spray- dried together in combination with the active ingredient. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. The compositions are thus particularly useful in the treatment of organophosphorus poisoning.
According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.
According to the invention, there is provided aa pharmaceuticaliy-acceptabie composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologicaliy-effective dosage amount of an adrenergic receptor modulator, or a pharmaceuticaliy-acceptabie salt thereof; and (b) a pharmaceuticaliy-acceptabie carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for, for example, transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.
According to the invention, there is provided aa pharmaceuticaliy-acceptabie composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologicaliy-effective dosage amount of an adrenergic receptor modulator, or a pharmaceuticaliy-acceptabie salt thereof; and (b) a pharmaceuticaliy-acceptabie carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for, for example, transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode. The method comprises treating the subject with an opioid agonist whilst managing their depression or depressive disorder using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable therapeutic medical and counseling content, namely, downloadable electronic data and multimedia files containing text, informational graphics, video and audio, and forms featuring information, instructions, charts, studies, and statistics in the fields of opioid dependence and addiction, treatment of opioid dependence and addiction, health and wellness information related to opioid dependence and addiction, and coaching and consulting for opioid dependence and addiction; downloadable electronic data files and downloadable multimedia files featuring information, instructions, charts, studies, and statistics in the fields of opioid dependence and addiction, treatment of opioid dependence and addiction, health and wellness information related to opioid dependence and addiction, and coaching and consulting for opioid dependence and addiction; downloadable electronic publications, namely, newsletters and written articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment Providing a website featuring digital therapeutic technology that enables users to treat and receive treatment for opioid dependence and opioid addiction; providing an online non-downloadable digital therapeutic software platform for providing behavioral health services in the nature of coaching, counseling, and advice in the field of opioid dependence, addiction and treatment; providing online non-downloadable computer programs for managing digital therapeutic and medical content in the field of opioid dependence and addiction and the field of treatment of opioid dependence and addiction; providing online non-downloadable software for accessing digital therapeutic resources in the treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for use in facilitating treatment and custom design and management of patient treatment for opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for collecting information and data from and providing addiction information and treatment services to patients; providing a website featuring non-downloadable software for providing telehealth, remote care, and virtual health care services; providing a web hosting digital therapeutic platform for providing behavioral health and medical services in the treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software, namely, an interactive digital healthcare software platform for providing behavioral health services to patients; providing online non-downloadable software to facilitate custom design and provision of addiction counseling, therapy, healthcare and support services in treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for collecting, aggregating and analyzing medical, healthcare and addiction treatment data Therapeutic services, namely, medical counseling, psychological counseling, medical advice, and medical information provided to patients with, and caregivers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and medical assistance services relating to the treatment of opioid dependent and addicted patients and their families; therapeutic services, namely, providing medical counseling, psychological counseling, medical advice, and medical information provided to patients and caregivers treating opioid dependence and opioid addiction delivered via non-downloadable software
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable therapeutic medical and counseling content, namely, downloadable electronic data and multimedia files containing text, informational graphics, video and audio, and forms featuring information, instructions, charts, studies, and statistics in the fields of opioid dependence and addiction, treatment of opioid dependence and addiction, health and wellness information related to opioid dependence and addiction, and coaching and consulting for opioid dependence and addiction; downloadable electronic data files and downloadable multimedia files featuring information, instructions, charts, studies, and statistics in the fields of opioid dependence and addiction, treatment of opioid dependence and addiction, health and wellness information related to opioid dependence and addiction, and coaching and consulting for opioid dependence and addiction; downloadable electronic publications, namely, newsletters and written articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment Providing a website featuring digital therapeutic technology that enables users to treat and receive treatment for opioid dependence and opioid addiction; providing an online non-downloadable digital therapeutic software platform for providing behavioral health services in the nature of coaching, counseling, and advice in the field of opioid dependence, addiction and treatment; providing online non-downloadable computer programs for managing digital therapeutic and medical content in the field of opioid dependence and addiction and the field of treatment of opioid dependence and addiction; providing online non-downloadable software for accessing digital therapeutic resources in the treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for use in facilitating treatment and custom design and management of patient treatment for opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for collecting information and data from and providing addiction information and treatment services to patients; providing a website featuring non-downloadable software for providing telehealth, remote care, and virtual health care services; providing a web hosting digital therapeutic platform for providing behavioral health and medical services in the treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software, namely, an interactive digital healthcare software platform for providing behavioral health services to patients; providing online non-downloadable software to facilitate custom design and provision of addiction counseling, therapy, healthcare and support services in treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for collecting, aggregating and analyzing medical, healthcare and addiction treatment data Therapeutic services, namely, medical counseling, psychological counseling, medical advice, and medical information provided to patients with, and caregivers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and medical assistance services relating to the treatment of opioid dependent and addicted patients and their families; therapeutic services, namely, providing medical counseling, psychological counseling, medical advice, and medical information provided to patients and caregivers treating opioid dependence and opioid addiction delivered via non-downloadable software
(b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material.
Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
09 - Scientific and electric apparatus and instruments
Goods & Services
Downloadable, printable therapeutic medical and counseling content, namely, downloadable files containing printable text and information graphics, downloadable forms, downloadable electronic data files and downloadable multimedia files containing text and graphics all featuring information, instructions, charts, studies, data in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, related health and wellness, and coaching and consulting information therefor; downloadable electronic publications, namely, downloadable newsletters and written articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations. Development of pharmaceutical preparations; research and development in the pharmaceutical fields; research and development of drug delivery platforms.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable, printable therapeutic medical and counseling
content, namely, information, forms, instructions, charts,
studies, data and related coaching and advice in the field
of opioid dependence and addiction, treatment of opioid
dependence and addiction, and related health and wellness;
electronic publications, namely, newsletters and articles
for use by medical professionals and patients in the field
of field of opioid dependence, addiction and treatment. Providing of training and further education in the nature of
virtual lectures in the field of medicine, health and
wellness for users in the medical fields with the aid of
software; further education in the nature of courses,
webinars, seminars, and workshops in the field of medicine,
health and wellness for patients suffering from opioid
addiction and for medical personnel specialized on the
treatment of opioid addiction. Providing a website featuring digital therapeutic technology
for treating opioid dependence and opioid addiction (terms
considered too vague by the International Bureau - rule 13
(2) (b) of the Regulations); providing an online digital
therapeutic platform for providing behavioral health
services, namely coaching, counseling, advice in the field
of opioid dependence, addiction and treatment (terms
considered too vague by the International Bureau - rule 13
(2) (b) of the Regulations); conducting medical and
scientific and technological research in the field of opioid
dependence and opioid addiction; conducting technological
research and design of digital therapeutics, namely
computer-based interactive and online psychological
intervention and counseling in the field of opioid
dependence and addiction; providing temporary use of
non-downloadable computer programs for administration of
digital therapeutic and medical content in the field of
opioid dependence and addiction and the treatment of opioid
dependence and addiction. Therapeutic services, namely, medical counselling,
psychological counselling, medical advice and medical
information provided to patients with, and care givers
treating, opioid dependence and opioid addiction;
computer-based interactive medical support services, namely,
providing online medical advice and assisting with treatment
of opioid dependent and addicted patients and their
families.
According to the invention, there is provided a pharmaceutica!!y-acceptab!e composition which is preferably in the form of a spray-dried powder comprising a mixture of: (a) a pharmaco!ogica!!y-effective dosage amount of at least one pharmaceutically- active compound; and (b) a pharmaceutioai!y-acceptab!e carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucossl drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically- acceptab!e carriers in this regard include lactose or trehalose and dextrins (e.g. cydodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more aikyi saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.
According to the invention, there is provided a pharmaceutica!!y-acceptab!e composition which is preferably in the form of a spray-dried powder comprising a mixture of: (a) a pharmaco!ogica!!y-effective dosage amount of at least one pharmaceutically- active compound; and (b) a pharmaceutioai!y-acceptab!e carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucossl drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically- acceptab!e carriers in this regard include lactose or trehalose and dextrins (e.g. cydodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more aikyi saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations. Development of pharmaceutical preparations; research and development in the pharmaceutical fields; research and development of drug delivery platforms.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Downloadable printable therapeutic medical and counseling content, namely, medical information, medical forms, instruction manuals, medical information charts, studies, data and related coaching and advice in form of newsletters, periodicals, pamphlets, research reports and brochures all in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment. (1) Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields via computer software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction.
(2) Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction.
(3) Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable therapeutic medical and counseling content, namely, downloadable written and graphic materials, downloadable forms, downloadable electronic data files, downloadable multimedia files featuring information, instructions, charts, studies, data in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, related health and wellness, and coaching and consulting information therefor; downloadable electronic publications, namely, downloadable newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction Providing a website featuring digital therapeutic technology for the treatment of opioid dependence and opioid addiction; providing an online non-downloadable digital therapeutic software platform for providing behavioral health services in the nature of coaching, counseling, advice in the field of opioid dependence, addiction and treatment; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely, technological research and design of computer software for interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and medical assistance services relating to the treatment of opioid dependent and addicted patients and their families
41 - Education, entertainment, sporting and cultural services
Goods & Services
Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable, printable therapeutic medical and counseling
content, namely, information, forms, instructions, charts,
studies, data and related coaching and advice in the field
of opioid dependence and addiction, treatment of opioid
dependence and addiction, and related health and wellness;
electronic publications, namely, newsletters and articles
for use by medical professionals and patients in the field
of opioid dependence, addiction and treatment. Providing of training and further education in the nature of
virtual lectures in the field of medicine, health and
wellness for users in the medical fields with the aid of
software; further education in the nature of courses,
webinars, seminars, and workshops in the field of medicine,
health and wellness for patients suffering from opioid
addiction and for medical personnel specialized on the
treatment of opioid addiction. Providing a website featuring digital therapeutic technology
for treating opioid dependence and opioid addiction;
conducting medical and scientific and technological research
in the field of opioid dependence and opioid addiction;
conducting technological research and design of digital
therapeutics, namely computer-based interactive and online
psychological intervention and counseling in the field of
opioid dependence and addiction; providing temporary use of
non-downloadable computer programs for administration of
digital therapeutic and medical content in the field of
opioid dependence and addiction and the treatment of opioid
dependence and addiction. Therapeutic services, namely, medical counselling,
psychological counselling, medical advice and medical
information provided to patients with, and care givers
treating, opioid dependence and opioid addiction; providing
an online digital therapeutic platform for providing
behavioral health services, namely coaching, counseling,
advice in the field of opioid dependence, addiction and
treatment; computer-based interactive medical support
services, namely, providing online medical advice and
assisting with treatment of opioid dependent and addicted
patients and their families.
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically- effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. Said compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. Said compositions and applicators may be employed in the treatment of opioid overdose in subjects.
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically- effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. Said compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. Said compositions and applicators may be employed in the treatment of opioid overdose in subjects.
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Downloadable, therapeutic medical and counseling information in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; downloadable therapeutic medical and counseling studies in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness in the form of charts; downloadable therapeutic medical coaching and advice in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness in the form of instructions, charts and studies; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment (1) Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction
(2) Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction
(3) Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; Computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable, printable therapeutic medical and counseling content, namely, information, forms, instructions, charts, studies, data and related coaching and advice in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment. Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction. Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction. Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; Computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable, printable therapeutic medical and counseling content, namely, information, forms, instructions, charts, studies, data and related coaching and advice in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment. Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction. Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction. Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; Computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families.
8-228-22 fatty acid, such as oleic acid or myristic acid. The dosage forms are useful in the treatment of a variety of psychotic conditions, such as schizophrenia, bipolar disorder and ADHD.
There are provided solid, pharmaceutically-acceptable compositions suitable for peroral administration to the gastrointestinal tract, in which (a) an opioid analgesic and (b) a sucrose ester with a hydrophilic-lipophilic balance value of between 6 and 20 are both dissolved and/or dispersed in a C12-22 fatty acid, which fatty acid is a solid at about 37°C, such as myristic acid, lauric acid, palmitic acid, stearic acid, arachidic acid and behenic acid. The dosage forms are abuse-resistant and are useful in the treatment of inter alia opioid dependency/addiction and/or pain.
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Therapeutic services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; therapeutic services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction via an online digital platform
There is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist. The pharmaceutical composition includes a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The pharmaceutical composition is preferably in the form of a powder produced by spray-drying, which is subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. The pharmaceutical composition may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Advertising; advertising of pharmaceutical products;
demonstration of goods for promotional purposes;
distribution of samples; provision of commercial
information. Educational services, namely, providing instructional
courses and seminars in the field of opioid dependence and
opioid addiction to enable further self-directed education
and recovery; providing training in the field of opioid
dependence and opioid addiction to enable further
self-directed education and recovery. Medical services in the nature of medical support services,
namely, medical counseling, psychological counseling,
medical advice and medical information provided to patients
with dependence and opioid addiction and to their care
givers.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Advertising; advertising of pharmaceutical products;
demonstration of goods for promotional purposes;
distribution of samples; provision of commercial
information. Educational services, namely, providing instructional
courses and seminars in the field of opioid dependence and
opioid addiction to enable further self-directed education
and recovery; providing training in the field of opioid
dependence and opioid addiction to enable further
self-directed education and recovery. Medical services in the nature of medical support services,
namely, medical counseling, psychological counseling,
medical advice and medical information provided to patients
with dependence and opioid addiction and to their care
givers.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Advertising; advertising of pharmaceutical products; demonstration of goods for promotional purposes; distribution of samples; provision of commercial information. Educational services, namely, providing instructional courses and seminars in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery; providing training in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery. Medical services in the nature of medical support services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with dependence and opioid addiction and to their care givers.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Advertising; advertising of pharmaceutical products; demonstration of goods for promotional purposes; distribution of samples; provision of commercial information. Educational services, namely, providing instructional courses and seminars in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery; providing training in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery. Medical services in the nature of medical support services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with dependence and opioid addiction and to their care givers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for human use, namely, preparations for the treatment of opioid dependence, preparations for the treatment of drug addiction, and opiate antagonist preparations for the treatment of opioid dependence and addiction; pain relief preparations and pain killers for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for human use, namely, preparations for the treatment of opioid dependence, preparations for the treatment of drug addiction, and opiate antagonist preparations for the treatment of opioid dependence and addiction; pain relief preparations and pain killers for human use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Pharmaceutical preparations, namely for the treatment of
heartburn, migraine, insomnia, urinary incontinence, asthma,
rhinitis, oesteoarthrosis, inflammatory diseases, chronic
obstructive pulmonary disease (COPD) opioid dependence,
cancer as well as pain relief and pain killers, to the
exclusion of anti-infectious products and antibiotics. Clinical research and professional expertise relating
thereto. Pharmaceutical services and professional expertise relating
thereto. Licensing within the field of medicines.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Pharmaceutical preparations, namely, for the treatment of [ heartburn, migraine, insomnia, urinary incontinence, asthma, rhinitis, oesteoarthrosis, inflammatory diseases, chronic obstructive pulmonary disease (COPD) ] opioid dependence [ , cancer as well as pain relief and pain killers, to the exclusion of anti-infectious products and antibiotics ] Conducting basic and clinical research in the field of medicine, pharmacology and testing of pharmaceuticals and consultation related thereto Pharmaceutical advice Licensing of intellectual property within the field of medicines
64.
NEW SUFENTANIL COMPOSITION FOR THE TREATMENT OF ACUTE PAIN
There is provided pharmaceutical compositions for the treatment of pain e.g. breakthrough pain which compositions comprise a mixture comprising: (a) microparticles of sufentanil, or a pharmaceutically acceptable salt thereof, which microparticles are presented on the surfaces of larger carrier particles; (b) a water-soluble weak base; and (c) a compound which is a weak acid, which acid is presented in intimate mixture with the microparticles of sufentanil or salt thereof. The composition may further comprise a disintegrant. The acid is preferably citric acid.
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
65.
NEW ALFENTANIL COMPOSITION FOR THE TREATMENT OF ACUTE PAIN
There is provided pharmaceutical compositions for the treatment of pain e.g. short-term pain, which compositions comprise a mixture comprising: (a) microparticles of alfentanil, or a pharmaceutically acceptable salt thereof, which microparticles are presented on the surfaces of larger carrier particles; (b) a water-soluble weak base; and (c) a compound which is a weak acid, which acid is presented in intimate mixture with the microparticles of alfentanil or salt thereof. The composition may further comprise a disintegrant. The acid is preferably citric acid.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly- acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly- acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 9/00 - Medicinal preparations characterised by special physical form
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Pharmaceutical preparations, namely for the treatment of heartburn, migraine, insomnia, urinary incontinence, asthma, rhinitis, oesteoarthrosis, inflammatory diseases, chronic obstructive pulmonary disease (COPD) opioid dependence, cancer as well as pain relief and pain killers, to the exclusion of anti-infectious products and antibiotics. Clinical research and professional expertise relating thereto. Pharmaceutical services and professional expertise relating thereto. Licensing within the field of medicines.
74.
NEW PHARMACEUTICAL DOSAGE FORM FOR THE TREATMENT OF GASTRIC ACID-RELATED DISORDERS
According to the invention there is provided a pharmaceutical composition for peroral administration to the gastrointestinal tract comprising: (i) a plurality of granules comprising a pharmacologically effective amount of a micronised H2 receptor antagonist or a pharmaceutically acceptable salt thereof granulated together with a disintegrant; and (ii) a pharmaceutically acceptable carrier, wherein the granules (i) are distributed homogeneously within the carrier (ii). The compositions of the invention are particularly useful in the treatment of gastric acid secretion-related disorders, such as gastro-esophageal reflux disease.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
According to the invention there is provided a single unit oral dosage form comprising: (a) a first component comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and an enteric substance positioned to protect the proton pump inhibitor from the acidic environment of the stomach; (b) a second component comprising an H2 receptor antagonist or a pharmaceutically acceptable salt thereof; and (c) a physical and/or chemical barrier located between the first and second components, and preventing said components from interacting with each other. The dosage forms of the invention are particularly useful in the treatment of gastric acid secretion-related disorders, such as gastro-esophageal reflux disease.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
76.
COMPOSITION FOR SUSTAINED DRUG DELIVERY COMPRISING GEOPOLYMERIC BINDER
The present invention relates to a sustained release medical composition comprising an active pharmaceutical ingredient and a geopolymeric binder. Preferably the active pharmaceutical ingredient is combined with the geopolymeric binder during the formation of that binder.
There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use, food for babies; plasters,
materials for dressings; material for stopping teeth, dental
wax; disinfectants.
79.
Pharmaceutical formulations useful in the treatment of insomnia
There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.
The present invention relates to improved compositions for transmucosal administration, the compositions enabling rapid and efficient uptake of a therapeutically active agent to provide a rapid, effectively durable, predictable and consistent therapeutic effect. In particular, the compositions are intended for buccal and/or sublingual delivery. The invention is particularly suitable for administering therapeutically active agents which have an effect on the central nervous system and even more particularly where rapid onset of this effect is desired or beneficial. The invention is also particularly suitable for administering active agents in low solubility base or acid forms.
There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; food for babies; plasters,
materials for dressing; material for stopping teeth, dental
wax; disinfectants; preparations for destroying vermin;
fungicides; herbicides.
